3997 related articles for article (PubMed ID: 16822992)
1. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
[TBL] [Abstract][Full Text] [Related]
2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
3. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
[TBL] [Abstract][Full Text] [Related]
4. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
6. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
10. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Chua YJ; Cunningham D
Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
[No Abstract] [Full Text] [Related]
11. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
12. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A
Br J Cancer; 1995 Mar; 71(3):583-6. PubMed ID: 7880742
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
[TBL] [Abstract][Full Text] [Related]
15. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Briasoulis E; Fatouros M; Roukos DH
Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
[No Abstract] [Full Text] [Related]
16. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Macdonald JS; Smalley SR; Benedetti J; Hundahl SA; Estes NC; Stemmermann GN; Haller DG; Ajani JA; Gunderson LL; Jessup JM; Martenson JA
N Engl J Med; 2001 Sep; 345(10):725-30. PubMed ID: 11547741
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Mongan AM; Kalachand R; King S; O'Farrell NJ; Power D; Ravi N; Muldoon C; O'Byrne K; Reynolds JV
Ir J Med Sci; 2015 Jun; 184(2):417-23. PubMed ID: 24879337
[TBL] [Abstract][Full Text] [Related]
19. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
Ferri LE; Ades S; Alcindor T; Chasen M; Marcus V; Hickeson M; Artho G; Thirlwell MP
Ann Oncol; 2012 Jun; 23(6):1512-7. PubMed ID: 22039085
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
Melcher AA; Mort D; Maughan TS
Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]